will be commercially available or launched in the CE marked nations?

We haven't provided an update as I think, but we have talked about our bigger markets. Germany, the UK and France are our biggest markets, and then Spain and Benelux. and, you know, Italy and Switzerland, you know, these are all larger European markets. And as just for anybody who's not as familiar with our distribution, about two thirds of our businesses in the U.S., one third is international and probably 80% of our international business, maybe more than that, actually, probably 90% of our international business comes from Europe. So those bigger markets are the ones that, some number of those would be the first ones to come online first with AeroSeal. And the reason why you asked the question, Bill, is that we have the CE mark on AeroSeal, so we don't have the same regulatory path to market in those countries that we do in the United States.

Yeah, are you going to be launching it in those countries anytime soon? That's the real question.

I know, and the answer is that we will be launching sooner than we will be in the U.S. We will, we need to get on the other, those, so this, the CONVERT II trial is an international trial, and we have centers in most of the countries that I just mentioned. It's a global trial, so it's in the United States, it's across Europe, and in Australia. And so we will not be launching AeroSeal into... Two things are going to happen. One, the ConvertOne publication has been submitted for publication, so we're going to get that out before we're going to launch because we need to have some documentation of what people can expect when they use it. and then the second thing is that we need we will not be launching into any markets until we are done enrolling convert to patients in those markets so those are the those are sort of the rate limiters so and I'm not going to answer the follow-on question which is when specifically do we expect to enroll the last patients into convert to in Europe but that that would give you a sense of and, you know, the rough timeline when we would be considering commercializing in some number of European markets.

Okay, but if you complete enrollment in a given country next year, you could commercialize in that country if the trial's enrollment has been completed, even though it's not completed in other CE mark countries. Is that fair to assume?

Yeah, but we don't have a specific target. The specific targets we have in the trial is we're trying We do not establish a ratio of the distribution between the U.S. and OUS. We do not have a specific target in France or a specific target in the U.K. So it's really a question of when are we done enrolling OUS patients in Convert, at which point we'll move down the path, the commercialization questions. And it's not going to be a switch that will be thrown. There will be training that will happen. There will be normal launch activities happening. which would typically take 90 to 180 days or something before you'd start seeing folks up and running and adopting and buying. Okay.

All right. I'll stop on that. And last question for me, I'll give you an easy one. You got the debt facility in place with milestones you'll be able to access that. How are you thinking about the path to cash flow break even with your current cash and that debt facility access? Thanks for taking the questions.

Thanks, Bill. We feel good about our path to cash flow break-even. We believe that we have a clear path with the cash that we have on hand and an additional buffer with the access from the debt facility. With the capital that we have access to today, we feel like we can clearly get to cash flow break-even over the next few years. Thanks.

That does conclude the Q&A session for today. I would now like to turn the call back to Glen French for closing remarks.

Thank you, operator. In closing, I'd just like to say that we're focused and executing on the priorities that matter most. I'm pleased with the team we have, the path we are on to improve the trajectory of our business and the progress we're making. We remain focused on the well-defined work ahead, strengthening our sales organization, advancing our clinical programs, and continuing to improve our financial leverage. We are both confident in the strength of the business and in our team's ability to continue to effectively execute. Thank you all for your time and interest in Pulmonix, and to all Pulmonix employees around the world who work every day to improve the lives of patients with severe emphysema. Thank you.

This concludes today's conference call. Thank you for participating and you may now disconnect.